Stay updated on Pembrolizumab Combo in Ovary Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Ovary Cancer Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The site footer revision identifier was updated from v3.8.0 to v3.8.1, with no change to the clinical trial record content.
    Difference
    0.0%
    Check dated 2026-11-18T01:12:00.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The clinical trial page now displays the study record for a Phase II pembrolizumab, carboplatin, and paclitaxel trial for epithelial ovarian cancer, including its completed status, study design, eligibility criteria, and outcome measures.
    Difference
    62%
    Check dated 2026-11-10T20:16:49.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The footer’s displayed ClinicalTrials.gov revision changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T20:41:01.000Z thumbnail image
  4. Check
    30 days ago
    Change Detected
    Summary
    A site-wide NIH notice about the terminology transition from “AI” to “SI” appears above the page, which still displays a 403 error. The footer revision changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T20:47:48.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.0 to v3.7.1 on the 403 Forbidden page; no study details are shown.
    Difference
    0.2%
    Check dated 2026-10-06T21:48:35.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    The study page now loads a 403 Forbidden error instead of displaying the trial details, indicating the record is currently inaccessible. The error page is shown with the standard site chrome and a 403 message, preventing access to the study information.
    Difference
    20%
    Check dated 2026-09-22T23:09:50.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Ovary Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.